arrow
C

Cornelius F. Waller

University of Freiburg
H指数:49
被引数:9,206

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [68Ga]Ga-BCY25286

使用双环放射性示踪剂[68Ga]Ga-BCY25286对一名患有乳腺癌和肌肉浸润性尿路上皮膀胱癌的患者进行MT1-MMP首次人体PET成像

2025-12-010
PRE
Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial

局部晚期非小细胞肺癌中辐射估计剂量对免疫细胞的影响(EDRIC):一项多中心随机PET-Plan试验的二次分析

2025-07-010
OAAI
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma

感染或疫苗接种后SARS-CoV-2-Specific CD8 T细胞受损,但多发性骨髓瘤患者的混合T细胞免疫功能强大

2024-11-010
OAAI
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Sotorasib在KRAS G12C-mutated非小细胞肺癌: 来自德国同情使用计划的多中心现实世界经验

2024-04-018
OA
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

药物转运体OCTN1基因启动子中的SNP rs460089对伊马替尼治疗的慢性粒细胞白血病患者的无治疗缓解具有预后价值

LEUKEMIA
IF13.4
2023-12-213
OAAI
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
2023-09-220
OAAI
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

lurbinectedin和阿霉素联合化疗与医生选择的复发性小细胞肺癌患者 (ATLANTIS): 一项多中心,随机,开放标签的3期试验

2023-01-0154
PRE
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
2022-06-0412
OAAI
SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals
2022-04-280
OAAI
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
2021-11-185
OAAI
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
BREAST
IF7.9
2021-08-015
OAAI
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
Nature
IF48.5
2021-07-280
OAAI
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
2021-06-1410
OAAI